Eloxx Pharmaceuticals, Inc. secured financing with the lenders under its Loan and Security Agreement, dated as of September 30, 2021 (as amended, amended and restated, supplemented, or otherwise modified from time to time) for an aggregate of $3.175 million financing of which $500,000 has been funded in advance. This financing is in addition to the $288,00 financing closed in May and both financings have identical terms and conditions. This additional financing is intended to support the advancement of the company's clinical programs and provide funding for general corporate purposes.

The company expects to receive the remainder $2.675 million of bridge loan financing on or about July 12, 2024.